Pfizer and BioNTech require U.S. vaccine authorization for teens
Pfizer and BioNTech have become the first vaccines to require permission to use Covid-19 jab in teens in the U.S. in an effort to extend vaccines beyond adults, as officials seek to get students back to their classrooms as soon as possible.
The companies said Friday that they had asked the Food and Drug Administration for permission to use them for emergencies for teens between the ages of 12 and 15, who last week reported showing a phase 3 trial of the owner to 2,260 young teens between the ages of 12 and 15. Efficiency of 100 and a strong antibody response.
The BioNTech / Pfizer vaccine is already licensed in the U.S. for people over the age of 16, and pharmacists said the side effects of the trial were “generally consistent” between the ages of 16 and 25.
The companies said they plan to seek permission from other regulators in the coming days, “as a critical step in Pfizer’s and BioNTech’s ongoing efforts to expand efforts to vaccinate governments around the world.”
Incorporating children can lead to greater confidence in a massive return to classrooms, as many schools now offer mix face-to-face and online learning.
Schools in several areas of the U.S. have been completely or partially closed since the pandemic began, as the spread of the infection prevented teachers and parents from returning completely to face-to-face teaching.
Pfizer and BioNTech began dosing younger children with the vaccine last month, while six-month-olds are 11 years old, while other drug producers are also in different stages of testing children’s jabs.
Modern is experimenting with children under the age of six months, and Johnson & Johnson is doing a single-dose shot to teens ages 12 to 17, starting with teens ages 16 to 17.
This week, a children’s trial against the Oxford / AstraZeneca vaccine was conducted has paused The UK regulator, meanwhile, investigated the links between adult jab and blood clots.